Tradestie Institutional Equity Comparison Engine

XERS vs LCTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XERS Overall Edge

XERS Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xeris Biopharma Holdings, Inc. Common Stock (XERS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, XERS trades at 62.3x Forward P/E with 12.7% operating margin (+44.2% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, XERS sits in SURGE (12th %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
XERS 62.3x vs LCTX 30.7x Fwd P/E
Growth & Margin Winner XERS
Op Margin 12.7% vs -280.3% ยท YoY +44.2% vs -61.0%
Momentum & Technical Winner XERS
1Y +134.8% vs -53.7% ยท 52W Pos 94% vs 4%
Options & Structure Winner XERS
SURGE (12th %ile IV) vs BREAKDOWN (100th %ile IV)
XERS NASDAQ
Xeris Biopharma Holdings, Inc. Common Stock
Pharmaceutical Preparations
$16.62
-2.18% 1D
Market Cap $3.1B
1M Return +54.1%
1Y Return +134.75%
Forward P/E 62.3x
Unified AI Score
36.5 / 100 SELL
Tech 50.0 Fund 32.0 Flow 71.0 Mom 40.0
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XERS +134.75% LCTX -53.67% Spread: +188.42 pp (XERS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period XERS Revenue LCTX Revenue XERS Op. Margin LCTX Op. Margin Margin Edge
FY2018 N/A $0M N/A -837.9% LCTX
FY2019 N/A $0M N/A -1106.0% LCTX
FY2020 $20M $0M -414.5% -1448.4% XERS
FY2021 $50M $0M -232.2% -1133.6% XERS
FY2022 $110M $10M -74.3% -153.2% XERS
FY2023 $160M $10M -26.8% -276.5% XERS
FY2024 $200M $10M -16.6% -226.1% XERS
FY2025 $290M $10M 8.5% -251.6% XERS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XERS (4) vs LCTX (6)
Institutional Metric XERS LCTX Criterion Row Winner
Market Capitalization Scale $3.1B $212.1M Larger Scale XERS
Trailing P/E Ratio Valuation 86.2x 30.7x Lower Multiple LCTX
Forward P/E Ratio Valuation 62.3x 30.7x Lower Multiple LCTX
Revenue Growth (YoY) Growth +44.2% -61.0% Higher Growth XERS
Operating Margin (TTM) Profitability 12.7% -280.3% Higher Margin XERS
Net Profit Margin Profitability -1.8% 16.2% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency -27.1% 4.3% Higher ROE LCTX
52-Week Range Position Momentum 94% ($5โ€“$17) 4% ($1โ€“$2) Stronger Trend XERS
Beta / 30D Volatility Risk Regime -0.03ฮฒ ยท 104% Vol 1.36ฮฒ ยท 79% Vol Lower Realized Risk LCTX
Unified Institutional Score Composite Signal 36.5 / 100 (SELL) 58.9 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XERS vs LCTX Buy Guide
XERS SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live XERS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XERS nor LCTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.